Inflammatory biomarkers and progression of diabetic retinopathy in African Americans with type 1 diabetes

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 8, 2013, Pages 5471-5480

  Roy, Monique S ^a   Janal, Malvin N ^b   Crosby, Juan ^c   Donnelly, Robert ^c  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

^b NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

African Americans; Biomarkers; Diabetic retinopathy; Incidence; Inflammation

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EOTAXIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOSYLATED HEMOGLOBIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; PLATELET DERIVED GROWTH FACTOR; RANTES; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; EYE EXAMINATION; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INCIDENCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; REGRESSION ANALYSIS; STRUCTURED INTERVIEW;

AFRICAN AMERICANS; BIOMARKERS; DIABETIC RETINOPATHY; INCIDENCE; INFLAMMATION;

ADULT; AFRICAN AMERICANS; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; DISEASE PROGRESSION; HUMANS; INCIDENCE; INFLAMMATION; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84881494911     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-12212     Document Type: Article

References (66)

1. Kuwabara T, Cogan D. Retinal vascular patterns. VI. Mural cells of the retinal capillaries. Arch Ophthalmol. 1963;69:492-502.
2. Gardner T, Antonetti D, Barber A, et al. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol. 2002;47(suppl 2): S253-S262.
3. Adamis A. Is diabetic retinopathy an inflammatory disease? More work remains to prove this hypothesis. Br J Ophthalmol. 2002;86:363-365.
4. Tang J, Kern T. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30:343-358.
5. Schröder S, Palinski W, Schmid-Schöebein G. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol. 1991;139:81-100.
6. Miyamoto K, Ogura Y. Pathogenetic potential of leukocytes in diabetic retinopathy. Semin Ophthalmol. 1999;14:233-239.
7. Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A. 1999;96:10836-10841.
8. Joussen A, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001;158:147-152.
9. Joussen A, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol. 2002; 160:501-509.
10. Joussen A, Poulaki V, Le M, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18:1450-1452.
11. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroids attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci. 2005; 46:1440-1444.
12. Joussen A, Poulaki V, Mitsiades N, et al. Nonsteroidal antiinflammatory drugs prevent early diabetic retinopathy via TNF-α suppression. FASEB J. 2002;16:438-440.
13. Abu El Asrar A, Maimone D, Morse P, Gregory S, Reder AT. Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am J Ophthalmol. 1992;114:731-736.
14. Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A. TNF-alpha level in the vitreous body. Increase in neovascular eye diseases and proliferative diabetic retinopathy. Med Klin. 1995;90:134-137.
15. Elner S, Elner V, Jaffe G, Stuart A, Kunkel SL, Streiter RM. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res. 1995;14:1045-1053.
16. Elner S, Strieter R, Bian Z, et al. Interferon-induced protein 10 and interleukin 8. C-X-C chemokines present in proliferative diabetic retinopathy. Arch Ophthalmol. 1998;116:1597-1601.
17. Limb A, Hickman-Casey J, Hollifield R, Chignell A. Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 1999;40: 2453-2457.
18. Yuuki T, Kanda T, Kimura Y, et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications. 2001;15:257-259.
19. Abu El-Asrar A, Struyf S, Kangave D, Geboes K, Van Damme J. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur Cytokine Netw. 2006;17:155-165.
20. Demircan N, Safran B, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumor necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye. 2006;20:1366-1369.
21. Maier R, Weger M, Haller-Schober EM, et al. Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Mol Vis. 2008; 14:637-643.
22. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology. 2005;112:806-816.
23. Wakabayashi Y, Usui Y, Okunuki Y, et al. Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. Retina. 2010;30:339-344.
24. Zhou J, Wang S, Xia X. Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res. 2012;37:416-420.
25. Yoshimura T, Sonoda KH, Sugahara M, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One. 2009;4(12):e8158.
26. Baharivand N, Zarghami N, Panahi F, Dokht Ghafari MY, Mahdavi Fard A, Mohajeri A. Relationship between vitreous and serum vascular endothelial growth factor levels, control of diabetes and microalbuminuria in proliferative diabetic retinopathy. Clin Ophthalmol. 2012;6:185-191.
27. Olson J, Whitelaw C, McHardy K, Pearson DW, Forrester JV. Soluble leucocyte adhesion molecules in diabetic retinopathy stimulate retinal capillary endothelial cell migration. Diabetologia. 1997;40:1166-1171.
28. Matsumoto K, Sera Y, Ueki Y, Inukai G, Niiro E, Miyaki S. Comparison of serum concentrations of soluble adhesion molecules in diabetic microangiopathy and macroangiopathy. Diabet Med. 2002;19:822-826.
29. Doganay S, Everklioglu C, Er H, Türköz Y, et al. Comparison of serum NO, TNF-α, IL-1, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye. 2002;16: 163-170.
30. van Hecke M, Dekker J, Nijpels G, et al. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia. 2005;48:1300-1306.
31. Meleth A, Agron E, Chan CC, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005;46:4295-4301.
32. Schram M, Chaturvedi N, Schalkwijk C, et al. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1diabetes-The EURODIAB Prospective Complications Study. Diabetologia. 2005;48:370-378.
33. Targher G, Bertolini L, Zoppini G, Zennari L, Falezza G. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med. 2005;22:999-1004.
34. Soedamah-Muthu S, Chaturvedi N, Schalkwijk C, et al. EURODIAB Prospective Complications Study group. Soluble vascular cell adhesion molecule-1 and soluble E-selectin are associated with micro-and macrovascular complications in type 1 diabetic patients. J Diabetes Complications. 2006;20:188-195.
35. Spijkerman A, Gall M, Tarnow L, et al. Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in type 2 diabetes. Diab Med. 2007;24:969-976.
36. Zorena K, Mysliwska J, Mysliwiec M, et al. Serum TNF-alpha level predicts nonproliferative diabetic retinopathy in children. Mediators Inflamm. 2007;2007;92196.
37. Gustavsson C, Agardh E, Bengtsson B, Agardh CD. TNF-α is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J Diabetes Complications. 2008;22: 309-316.
38. Ozturk B, Bozkurt B, Kerimoglu H, Okka M, Kamis U, Gunduz K. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Mol Vis. 2009;15:1906-1914.
39. Koleva-Georgieva D, Sivkova N, Terzieva D. Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy. Folia Med (Plovdiv). 2011;53:44-50.
40. Pearson P, Comstock T, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled, clinical trial. Ophthalmology. 2011;118:1580-1587.
41. Nguyen Q, Shah S, Khwaja A, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146-2151.
42. Klein B, Knudtson M, Tsai M, Klein R. The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy. Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol. 2009; 127:1175-1182.
43. Muni R, Kohly R, Lee E, Manson J, Semba R, Schaumberg D. Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the Diabetes Control and Complications Trial. JAMA Ophthalmol. 2013;131:514-521.
44. Roy M. Diabetic retinopathy in African Americans with type 1 diabetes: The New Jersey 725. I. Methodology, population, frequency of retinopathy and visual impairment. Arch Ophthalmol. 2000;118:97-104.
45. Roy M. Diabetic retinopathy in African Americans with type 1 diabetes: The New Jersey 725. II. Risk factors. Arch Ophthalmol. 2000;118:105-115.
46. Winter W, Maclaren N, Riley W, Clarke D, Kappy M, Spillar R. Maturity-onset of youth in Black Americans. N Engl J Med. 1987;316:285-291.
47. Roy M, Affouf M. Six-year progression of retinopathy and associated risk factors in African American patients with type 1 diabetes mellitus: the New Jersey 725. Arch Ophthalmol. 2006;124:1297-306.
48. Canner P, Borhani N, Oberman A, et al. The Hypertension Prevention Trial: assessment of the quality of blood pressure measurements. Am J Epidemiol. 1991;134:379-92.
49. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification. ETDRS Report Number 10. Ophthalmology. 1991;98:786-780.
50. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS Report Number 12. Ophthalmology. 1991;98:823-833.
51. Roy M, Peng B, Roy A. Risk factors for coronary disease and stroke in previously hospitalized African-Americans with type 1 diabetes: a 6-year follow-up. Diabet Med. 2007;24:1361-1368.
52. Roy M, Klein R, Janal M. Retinal venular diameter as an early indicator of progression to proliferative diabetic retinopathy with and without high-risk characteristics in African Americans with type 1diabetes. Arch Ophthalmol. 2011;129:8-15.
53. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta. 2006; 368:33-47.
54. Albertini JP, Valensi P, Lormeau B, et al. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment. Diabetes Care. 1998;21:1008-1013.
55. Roldan V, Marin F, Lip G, Blann A. Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost. 2003;90:1007-1020.
56. Simon S, Green C. Molecular mechanics and dynamics of leukocyte recruitment during inflammation. Annu Rev Biomed Eng. 2005;7:151-185.
57. Barouch F, Miyamoto K, Allport J, et al. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci. 2000;41:1153-1158.
58. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci. 2003;44: 2155-2162.
59. Sfikakis P, Grigoropoulos V, Emfietzoglou I, et al. Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care. 2010;33:1523-1528.
60. Huang H, Gandhi J, Zhong X, et al. TNF alpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci. 2011;52:1336-1344.
61. Tracey K, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med. 1994;45:491-503.
62. Adamis A, Berman A. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008;30:65-84.
63. Moore T, Moore J, Kaji Y, et al. The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci. 2003;44:4457-4464.
64. Chen W, Jump D, Grant M, Esselman WJ, Busik JV. Dyslipidemia, but not hyperglycemia, induces inflammatory adhesion molecules in human retinal vascular endothelial cells. Invest Ophthalmol Vis Sci. 2003;44:5016-5022.
65. Nishiwaki A, Ueda T, Ugawa S, Shimada S, Ogura Y. Upregulation of P-selectin and intercellular adhesion molecule-1 after retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci. 2003;44:4931-4935.
66. Flower L, Ahuja R, Humphries S, Mohamed-Ali V. Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-α and leptin. Cytokine. 2000;12:1712-1716.